You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia

    SBC: Iveena Delivery Systems, Inc.            Topic: NEI

    Project Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder

    SBC: PHOENIX PHARMALABS, INC.            Topic: NIDA

    Abstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Compact Liquid Chromatography for Routine Screening in Drug Treatment Centers

    SBC: AXCEND LLC            Topic: NIDA

    Project Summary The Substance Abuse and Mental Health Services Administration (SAMHSA) has set guidelines for illicit drug monitoring for both screening and confirmatory tests. Point-of-care (POC) screening assays usually rely upon immunoassays that lack specificity among compounds in a given drug class. Confirmation testing usually employs chromatography coupled to mass spectrometry (MS), which i ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer

    SBC: Kuda Therapeutics, Inc.            Topic: NCI

    Abstract Kidney cancer is the 8th most common cancer in the US population, of which clear cell renal cell carcinoma (ccRCC) is the most common subtype. ccRCC is highly refractory to standard chemotherapy and radiation, and patients with advanced or metastatic tumors have a 5-year survival rate of just 14%. ccRCC is typically initiated by inactivation of the von Hippel Lindau (VHL) tumor suppressor ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. An oral TNFα inhibitor for inflammatory bowel disease

    SBC: D BioTherapeutics, LLC            Topic: 300

    Project Summary Inflammatory bowel disease is a group of disorders (Crohn’s disease and Ulcerative Colitis) that are associated with substantial morbidity and disability for millions of people worldwide. Although multiple biologic agents and small molecules are approved for the treatment, anti-TNF monoclonal antibodies remain first line therapy. Yet, clinical benefit from these agents is lost ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Development and Pre-Clinical Testing of Antimicrobial PEKK/Silicon Nitride Trauma Plates with Carbon Fiber Reinforcement

    SBC: SINTX TECHNOLOGIES, INC.            Topic: NIAMS

    PROJECT SUMMARY—More than 2 million Americans are hospitalized each year with bone fractures, and many more undergo outpatient procedures for fracture reduction and fixation. Some injuries can be treated with closed reduction and splinting or casting to immobilize the bone during healing. However, at some sites, more than half of fractures require open reduction and internal fixation. Despite ad ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Joyuus: A Web-based Tool for Postpartum Care Self-care to Address the Complex Needs of Underserved Women

    SBC: JOYUUS, LLC            Topic: 100

    PROJECT SUMMARY/ABSTRACT In the United States, the postpartum period is a critical time for both maternal and child health; the US maternal mortality rate is the highest among other developed, high-income countries. More than half of all maternal deaths occur postpartum, from one day to one year after birth.1-9 There are vast racial and ethnic disparities in maternal mortality and severe morbidity ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Dual-Tracer PET Tumor Imaging

    SBC: MULTIFUNCTIONAL IMAGING, LLC            Topic: 102

    AbstractPositron emission tomography (PET, including PET/CT and PET/MRI) with 18F-fluorodeoxyglucose (FDG) plays a key role in diagnosing and staging a wide variety of malignant tumors, assessing tumor grade, and evaluating response to therapy. The advent of other recently-approved tracers, particularly those with theranostic partners, is opening a new era of imaging where the uptake of PET tracer ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. A Next-Generation Therapeutic for Treatment of TNFα-mediated Inflammatory Diseases

    SBC: D BioTherapeutics, LLC            Topic: NIDDK

    PROJECT SUMMARY Inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC) are debilitating disorders that afflict ~1.3% of the U.S. population. Blockade of TNFα-driven inflammation with approved anti-TNFα biologics has been an effective IBD treatment for many patients. However, loss of efficacy due to anti-drug antibodies (ADAs) and toxicities such as serious infectio ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government